Rick Scott Highlights FDA Findings on Indian Medicine Factories and Drug Shortages

FDA Inspection Findings

• ⚠️ Flying birds, skittering lizards, and roaming cats were found in an Indian medicine manufacturing plant during an FDA inspection.
• 🚨 If such conditions were found in the U.S., a facility would be closed immediately.
• ❓ It is questioned whether the FDA would wave a violation for a foreign manufacturer if it could cause a drug shortage.

Drug Shortages and National Security

• 🏭 India is a major source of generic drug products for the U.S., and closing substandard plants could lead to product shortages.
• ⚡ This reliance on foreign manufacturing, particularly for Active Pharmaceutical Ingredients (APIs), poses a national security risk.
• 💊 The U.S. has lost its industrial base for API production over decades, leading to dependence on single foreign sources.

Civica's Model for Supply Chain Stability

• 🤝 Civica partners with hospitals through multi-year, fixed-volume contracts to provide stability to suppliers.
• 💰 These contracts include commitments to price, allowing suppliers to invest in quality and ensure market share.
• 📦 Civica maintains a six-month buffer inventory for every drug to mitigate shortages if a supplier exits the market.
• 🔍 Civica implements rigorous quality oversight of its suppliers, including facility visits and ongoing audits.

U.S. Pharmaceutical Manufacturing Concerns

• 🇺🇸 If a U.S. plant like the one discussed were closed, the nation would be completely dependent on India and China for antibiotics and finished dosage forms.
• ⏳ The U.S. currently maintains about a year's worth of API supply and finished goods at its facility.
• 📉 Foreign competition is seen as cutting costs to offer the lowest possible price, potentially compromising quality.
• 💰 Quality is not cheap, with significant investment required for maintaining high standards in manufacturing.